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Abstract
Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder of unknown etiology
and characterized by various clinical manifestations and multiple organ involvement. It has been
reported in association with POEMS syndrome and can progress to Kaposi's sarcoma or malignant
lymphoma. The disease runs a more aggressive course and a poor prognosis. Optimal therapies
have not been well established up to now. We here reported a case of rare MCD complicated with
multiple myeloma who received bortezomib and achieved very good remission. To our knowledge,
this is the first report on MCD in the setting of multiple myeloma with good response to
bortezomib.
Background
Multicentric Castleman's disease (MCD) was first
described as an entity in 1978 by Gaba et al[1]. The clini-
cal manifestations of MCD are heterogeneous and usually
with multiple organ involvement. It has been reported in
association with POEMS syndrome (but never with MM
up to now) and can progress to Kaposi's sarcoma or malig-
nant lymphoma [2]. Treatment for MCD remains subop-
timal. Bortezomib is a novel proteasome inhibitor that
affects myeloma cell growth by NF-κB blockade [3]. Clin-
ical trials have clearly demonstrated that bortezomib is
active in patients with relapsed and refractory MM. To
explore the efficacy of bortezomib in MCD therapy, we
successfully treated a 70-year-old male patient who had
both MCD and multiple myeloma with bortezomib, and
a good remission was observed.
Case presentation
A 70-year-old male patient was admitted to our hospital
in May 2007 with chief complaints of left upper abdomen
distention for 1 year with progressive peripheral lymphad-
enopathy associated with 8 kg weigh loss over 7 months.
The patient had epigastric discomfort with no fever and
night sweat initially in May 2006. Abdominal computed
tomographic (CT) scan and ultrasonography revealed
splenomegaly and many enlarged retroperitoneal lymph
nodes. Bone marrow cytomorphologic examination and
biopsy at that time were normal. Subsequently, the disten-
tion increased gradually in severity and icteric sclera was
seen. Five months later, painless and slowly-enlarging
bilateral latero-cervical lymphadenopathy had developed.
He also had episodes with petechia throughout the whole
body accompanied with fatigue, low-grade fever and
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night-sweat in the last month. He never had numbness/
tingling in his limbs during the course of the illness.
Physical examination revealed a chronically-ill appear-
ance with enlarged lymph nodes in the cervical, supracla-
vicular, axillar, and inguinal regions, the biggest of which
was 3.5 cm × 2.5 cm in size. Splenomegaly (10 cm below
the left costal margin)with no hepatomegaly was also pal-
pated.
Blood counts showed mild anemia (hemoglobin, 99 g/L),
a white blood cell count of 2.3 × 109/L and a low platelet
count of 30 × 109/L. Serum protein was 112 g/L (albumin
23 g/L, globulin 89 g/L). Immunoelectrophoresis showed
monoclonal increase in serum immunoglobulin with
IgG-κ. The serum IgG, IgA, IgM, κ and λ values were 86.8,
0.73, 0.63, 26.3 and 10.5 g/L, respectively. The total
Bence-Jones protein in 24-hour urine was 1850 mg. The
serum β2-microglobulin level was 8.09 mg/L and CRP
level was 16.6 mg/L. Anti-nuclear antibodies and sero-
logic tests (Epstein-Barr virus, hepatitis B and C viruses,
cytomegalovirus and human immunodeficiency virus)
were negative. All of the serum tumor markers(CEA, AFP,
CA125, CA19-9, PSA, NSE) were negative. The thyroid
function tests of T3, T4 and TSH were normal.
Bone marrow cytomorphologic examination at this hos-
pitalization showed increased plasma cells at 11%. Bone
X-ray revealed low density foci on the skull (Figure 1).
Electromyelogram showed normal nerve conduction
velocity of cubital nerve and median nerve. Ultrasound
examination of the abdomen revealed marked splenome-
galy with 200 mm × 90 mm in size. Abdominal CT scan
confirmed splenomegaly and enlarged lymph nodes in
retroperitoneal regions. Biopsy of a cervical lymph node
revealed that the structure of lymph node was still existed
and most of the folliculus lymphaticus were infiltrated
with sheets of plasma cells both in the germinal centre
and in the interfollicular space, and absence of vascular
proliferation (Figure 2). Immunohistochemistry for the
mature plasma cell in the germinal centers showed
LCA(+), CD20(±), CD79(±), CD15(-), CD30(±), CD7(±),
MUM1(+), Vs38(+), Ki67(++), and polyclonal κ as well as
λ was positive (Figure 3). HHV-8 DNA was not detected
by nested PCR in the paraffin embedded tissue specimens.
The pathological diagnosis was plasma cell variant of Cas-
tleman's disease. With all these findings, the patient was
diagnosed to have MCD complicated with multiple mye-
loma (Durie-Salmon IIIA). After written informed con-
sent, the patient was given bortezomib (1.3 mg/m2) as an
intravenous bolus twice weekly for 2 weeks on days 1, 4,
8, and 11 in a 3–4 weeks cycle. He got partial remission
after two cycles. The serum IgG level, β2-microglobulin
and CRP level decrease to 45.2 g/L, 5.8 mg/L and 11.2 mg/
L, respectively. A 75% decrease in lymph nodes and
splenomegaly was noted. In order to increase the efficacy,
dexamethasone at a dose of 30 mg/day on days 1–4, 8–11
was given in combination with bortezomib at 3rd and 4th
cycle. The treatment was stopped after a total of 4 cycles.
Eighteen months after diagnosis, the patient was in very
good partial remission with no lymphadenopathy. The
serum IgG level was 23 g/L, β2-microglobulin was 2.1 mg/
L and CRP was 3.0 mg/L.
Discussion
MCD is more common in elder male (male/female is
2.5~13:1). It is generally of the plasma cell type or mixed
variant. MCD is a systemic disease with significant periph-
eral lymphadenopathy and hepatosplenomegaly, as well
as frequent fever, night sweats, fatigue and weight loss.
Abnormal laboratory findings include pancytopenia,
abnormal function of liver and kidney, raised CRP, IL-6
and hypergammaglobulinemia. However, monoclonal
X-ray revealed low density foci on the skull(posterior-ante- rior and lateral film) Figure 1
X-ray revealed low density foci on the skull(poste-
rior-anterior and lateral film).
Pathology of an enlarged cervical lymph node was compatible  with Castleman's disease, plasma cell type (H & E stain: 400×  and 1000×) Figure 2
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gammaglobulinemia is rare. In addition, it has been
reported in association with amyloidosis, nephrotic syn-
drome, Sjögren syndrome and POEMS syndrome and can
progress to Kaposi's sarcoma or malignant lymphoma.
The patient in this case was manifested with progressing
splenomegaly at first and followed with enlarged periph-
eral lymph nodes and general symptoms such as fatigue
and weight loss. Immunohistochemistry and pathology of
cervical lymph node revealed the diagnosis of MCD. In
addition, a monoclonal globulin spike of 86.8 g/L was
found on serum electrophoresis at visit with further iden-
tification as IgG and κ light chain by immunofixation
analysis. Marrow plasmacytosis of 11% plasma cells with
morphological abnormality were also seen. X-ray demon-
strated lytic bone lesions in the skull. So this patient was
diagnosed to have multiple myeloma with one major and
two minor WHO criteria. To our knowledge, there has
been no report of MCD together with multiple myeloma.
In 1996, Komatsu et al[4] reported a case with cervical
UCD complicated with benign monoclonal gammopa-
thy, which was presumed to be associated with increased
IL-6 or the primary manifestation of multiple myeloma.
Monoclonal gammopathy had occurred in Castleman's
disease with POEMS syndrome. However, no sign of
POEMS was found in this case, such as polyneuropathy,
endocrinopathy, skin changes and edema. He has no
autoimmune disorders, primary immune deficiency, HIV
infection and chronic nephropaty. We presumed that the
monoclonal gammopathy was probably one of the pro-
gressing features of MCD.
We could not measure serum IL-6 level due to the limita-
tion of our lab technology, nevertheless, according to the
increased level of CRP, the patient was inferred to have a
high level of IL-6 which has positive correlation with CRP.
In recent 10 years, IL-6 has been implicated in the patho-
physiology of MCD[5]. The role of IL-6 in genesis of mye-
loma is demonstrated. It causes B-cell proliferation
resulting in hyperplastic follicles and hence the enlarged
lymph nodes. IL-6 also induces an acute phase reaction
comprising increases in ESR, CRP and serum fibrinogen.
B-symptom is virtually always associated with increased
IL-6 levels. Dysregulated overproduction of IL-6 from ger-
minal center B cells is implicated in the pathogenesis of
plasma-cell-type Castleman's disease.
Although there is evidence that HHV-8 plays a significant
role in the pathogenesis of HIV-associated MCD. Defini-
tively establishing the causality of HHV-8 in the aetiology
of other MCD type will prove challenging. Our patient has
no evidence of HHV-8 infection, so we propose that the
two phenomenons are linked through mechanisms
involving IL-6, which could lead to future treatment
options.
The MCD plasma cell subtype runs a more aggressive
course with poor prognosis, and optimal therapies have
not been well established. A number of therapies have
been used for multicentric disease, including steroid-
monotherapy and combined chemotherapy [6,7]. Other
therapies include interferon-α[8], antiviral medica-
tions[9], anti-IL-6 monoclonal antibody[10] and human-
ized anti-human IL-6 receptor mono-clonal antibody
(MRA)[11]. All-trans retinoic acid[12], thalidomide[13]
and Rituximab [14-17] also have been reported. Most of
these reports included only a small number of patients.
Bortezomib has recently been shown to produce signifi-
cant responses in about one-third of patients with refrac-
tory and relapsed MM[18]. The mechanism of action of
bortezomib is thought in part to be due to selective inhi-
bition of the proteasome. This drug has been reported to
affect myeloma cell growth by NF-κB blockade, down reg-
ulation of cytokines such as IL-6[19]. IL-6 has been impli-
cated in the pathophysiology of MCD, as mentioned
above, providing a rationale for treatment of MCD with
bortezomib. Previous clinical trials have indicated that the
combination of bortezomib and dexamethasone may be
additive or possibly synergistic. After two cycle's treatment
in the current case, the enlarged lymph nodes disappeared
and splenomegaly decreased significantly. Bone marrow
cytomorphologic examination showed only 3% plasma
cell by ratio with normal morphology. It is noteworthy
that the level of CRP which has positive correlation with
IL-6 level decreased to normal range. It is likely that the
effect of bortezomib on MCD is due to inhibition of IL-6
secretion.
At the 18-month follow-up, the patient showed persistent
clinical improvement, with no B symptoms, weight gain,
disappearance of lymphadenopathy and improvement of
performance status. Therefore, this observation showed
that the combination of bortezomib and dexamethasone
has activity in MCD.
Immunohistochemistry showed Vs38(+) (400× and 1000×) Figure 3
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Conclusion
In summary, we reported the first case of MCD with mul-
tiple myeloma which had remarkable response to the
combination of bortezomib and dexamethasone. This
observation showed that the combination of bortezomib
and dexamethasone has activity in MCD.
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